SCHEMBL14022271

SCHEMBL14022271

Ic1ccnc2nc(-c3ccccc3)[nH]c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 1/20 0.54
PI4K2B Q8TCG2 1/20 0.54
PI4K2A Q9BTU6 1/20 0.54
PI4KB Q9UBF8 1/20 0.54
GSK3B P49841 2/20 0.49
PRMT5 O14744 5/20 0.48
ADORA3 P0DMS8 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
CSF1R P07333 2/20 0.46
AURKA O14965 2/20 0.46
FGFR1 P11362 1/20 0.45
FGFR2 P21802 1/20 0.45
XDH P47989 1/20 0.43
CAMKK1 Q8N5S9 1/20 0.43
CAMKK2 Q96RR4 1/20 0.43
MAPK13 O15264 1/20 0.41
RAF1 P04049 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK12 P53778 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14022269 0.80 PRMT5 (0.69) PI4KAPI4K2BPI4K2API4KBGSK3B
SCHEMBL28700989 0.80 PI4KA (0.62) PI4KAPI4K2BPI4K2API4KBGSK3B
SCHEMBL14022279 0.75 MAPK13 (0.42) PI4KAPI4K2BPI4K2API4KBGSK3B
SCHEMBL14022274 0.74 GSK3B (0.52) PI4KAPI4K2BPI4K2API4KBGSK3B
SCHEMBL28267366 0.72 NPC1 (0.55) PI4KAPI4K2BPI4K2API4KBGSK3B
SCHEMBL4046146 0.72 METAP2 (0.64) PI4KAPI4K2BPI4K2API4KBGSK3B
SCHEMBL1284270 0.70 AURKA (0.73) PRMT5AURKA
SCHEMBL9175738 0.70 PI4KA (1.00) PI4KAPI4K2BPI4K2API4KBGSK3B
SCHEMBL783654 0.70 PI4KA (0.67) PI4KAPI4K2BPI4K2API4KBGSK3B
SCHEMBL9731613 0.70 PI4KA (0.67) PI4KAPI4K2BPI4K2API4KBGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders GSK3B, PYGB, GSK3A PI4KA 172/4885PI4K2B 151/4885PI4K2A 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.